PHILADELPHIA,
June 22, 2017
/PRNewswire/ -- Aberdeen Singapore Fund, Inc. (the
"Fund") (NYSE: SGF), a closed-end equity fund, announced today
its performance data and portfolio composition as of May 31,
2017.
The Fund's total returns for various periods through
May 31, 2017 are provided
below. (All figures are based on distributions reinvested at
the dividend reinvestment price and are stated net-of-fees):
|
Cumulative as of 05/31/17
|
Annualized as of 05/31/17
|
|
1 Month
|
3 Month
|
YTD
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
Since Inception
|
NAV
|
2.5
|
7.3
|
20.2
|
19.7
|
0.0
|
5.1
|
2.1
|
5.1
|
Market Price
|
0.5
|
13.5
|
28.3
|
26.4
|
0.2
|
5.0
|
2.0
|
4.3
|
MSCI Singapore
|
3.8
|
6.4
|
18.1
|
18.6
|
-1.1
|
4.6
|
2.8
|
6.2
|
On May 31, 2017, the Fund's net
assets amounted to US$93.0 million
and the Fund's NAV per share was US$12.53.
As of May 31, 2017, the portfolio
was invested as follows:
Portfolio
Composition
|
Percent of
Net Assets
|
Financials
|
29.9
|
Real Estate
|
23.7
|
Industrials
|
22.7
|
Telecommunications
|
7.0
|
Health Care
|
4.6
|
Information Technology
|
4.4
|
Consumer Discretionary
|
3.4
|
Consumer Staples
|
2.0
|
Materials
|
0.3
|
Cash
|
2.1
|
The Fund's ten largest equity holdings as of May 31, 2017, representing 61.8% of net assets,
were:
Stock
|
Percent of
Net Assets
|
Oversea-Chinese Banking Corporation
|
11.1
|
DBS Group Holdings
|
8.6
|
City Developments
|
7.0
|
Singapore Telecom
|
7.0
|
United Overseas Bank
|
6.9
|
Jardine Matheson
|
5.7
|
Keppel Corporation
|
4.4
|
Venture Corporation
|
4.0
|
Raffles Medical Group
|
3.7
|
Singapore Technologies Engineering
|
3.4
|
Important Information
Aberdeen
Asset Management Inc. has prepared this report based on information
sources believed to be accurate and reliable. However, the
figures are unaudited and neither the Fund, Aberdeen Asset
Management Inc. (the Administrator), Aberdeen Asset Management Asia
Limited (the Investment Manager), nor any other person guarantees
their accuracy. Investors should seek their own professional
advice and should consider the investment objectives, risks,
charges and expenses before acting on this information.
The Investment Manager and Administrator are each a
wholly owned subsidiary of Aberdeen Asset Management PLC.
Aberdeen Asset Management PLC announced on March 6, 2017 that it entered into an agreement
with Standard Life plc to carry out an all-share merger, subject to
regulatory and other approvals. More information about the
potential merger can be found on Aberdeen's website at
www.aberdeen-asset.com. Aberdeen is a U.S. registered service mark
of Aberdeen Asset Management PLC.
Closed-end funds are traded on the secondary market
through one of the stock exchanges. The Fund's investment return
and principal value will fluctuate so that an investor's shares may
be worth more or less than the original cost. Shares of closed-end
funds may trade above (a premium) or below (a discount) the net
asset value (NAV) of the fund's portfolio. There is no assurance
that the Fund will achieve its investment objective.
Total return figures with distributions reinvested at the
dividend reinvestment price are stated net-of-fees and represents
past performance. Past performance is not indicative of
future results, current performance may be higher or
lower. Holdings are subject to change and are
provided for informational purposes only and should not be deemed
as a recommendation to buy or sell the securities
shown. Inception date July 31, 1990.
If you wish to receive this information electronically, please
contact: InvestorRelations@aberdeen-asset.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/aberdeen-singapore-fund-inc-announces-performance-data-and-portfolio-composition-300478652.html
SOURCE Aberdeen Singapore Fund, Inc.